Review the Unmet Needs and the Clinical and Commercial Factors Effecting Respiratory Syncytial Virus Through Key Opinion Leader's Comments
Posted on: Thursday, 27 September 2007, 06:00 CDT
Research and Markets (http://www.researchandmarkets.com/reports/c69681) has announced the addition of "Stakeholder Opinions: Respiratory Syncytial Virus (RSV) - A Market Yet to Reach its Full Potential" to their offering.
RSV mostly causes upper respiratory tract infections (URTI), resulting in the common cold. However, in certain risk groups, RSV can cause more severe lower respiratory tract infections (LRTI) leading to bronchiolitis. These risk groups include elderly people, patients with underlying pulmonary or cardiac disease, premature infants, children under four years old and immunocompromised patients.
Scope of this title:
Discusses disease background, providing insight in RSV epidemiology, etiology and symptoms
Gives a breakdown of RSV (hospitalization) prevalence in the seven major markets
Examines current diagnosis and treatment trends, providing physicians opinions
Examines the RSV pipeline by type treatment, prophylaxis and vaccines, including a short discussion of each pipeline product
Highlights of this title:
Some physicians do not value the importance of a correct RSV diagnosis, since there is no effective treatment available. Furthermore, the American Academy of Pediatrics does not recommend routine testing for RSV in bronchiolitis. However, there are reasons why proper diagnosis should be considered, and there is a range of tests available for that.
The RSV market is currently dominated by MedImmunes Synagis, a prophylactic monoclonal antibody. As RespiGams successor, Synagis was first launched in 1998 and now has sales of around $750 million per RSV season. Due to its high costs though, Synagis is only prescribed to a very limited group of individuals.
Although the most important unmet need in RSV is an effective treatment or vaccine, many companies have discontinued their developments in this field. Only two companies have an RSV treatment in clinical development (Novartis/Arrow Therapeutics and Alnylam) and MedImmune dominates the limited vaccine development.
Reasons to order your copy:
Gain insight into the issues of current diagnosis and treatment for RSV through key opinion leader comments
Review the unmet needs and the clinical and commercial factors driving new product decisions
Identify the opportunities and threats presented by the RSV pipeline and predict the future shape of the market
Report Breakdown
Chapter 1 - Executive Summary Chapter 2 - Disease Background Chapter 3 - Diagnosis Chapter 4 - Current Treatment And Prevention Option Chapter 5 - Future Trends
Appendix A - Bibliography Appendix B - Commercially Available Antigen Detection Assays
For more information visit http://www.researchandmarkets.com/reports/c69681
Source: Datamonitor
Source: Business Wire
Related Articles
- Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease
- Bapineuzumab To Become the First-to-Market Disease-Modifying Alzheimer's Drug After Flurizan's Discontinuation
- Research and Markets: Central Nervous System - Alzheimer Disease Drug Pipeline Report
- ''Autoimmune And Inflammation - Autoimmune Diseases Drug Pipeline Report'' Contains Detailed Information On The Current Drug Pipeline
- Newly Published Guidelines for Treatment of Heart Valve Disease Lower Recommended Age for Tissue Valve Recipients
- Study Shows Applied NeuroSolutions' Test Improves Early Detection and Accurate Diagnosis of Alzheimer's Disease
- Salix Announces Publication of Study Results Suggesting XIFAXAN(TM) Potential in Treatment of Active Crohn's Disease; Publication Contributes to Growing Body of Evidence Suggesting XIFAXAN(TM) Efficacy Beyond Travelers' Diarrhea
- Novartis Licenses Rights to Develop and Commercialize New Respiratory Syncytial Virus (RSV) Treatment
- BioLineRx In-Licenses Novel Technology From Galmed International for the Treatment of Fatty Liver Disease
- Proteomic Fingerprints for Potential Application to Early Diagnosis of Severe Acute Respiratory Syndrome
 |
 |
User Comments (0)
RSS Feeds